Catalio Capital Management

Activity in this selectioneuclidean-capital-095b3c13

By stage

Series C+3

Growth1

Series B1

Undisclosed1

Biotech3

Healthtech3

United States5

Australia1

6 in this selection

Jul 31

Developing best-in-class radiopharmaceuticals for cancer treatment

$70MSeries C

Role not disclosed

Jul 15

Develops lead-212 targeted alpha therapies to treat cancer

$315MSeries D

Role not disclosed

May 13

AI-enabled virtual specialty care platform for managing high-cost chronic conditions

$26MSeries B

Role not disclosed

Mar 17

Develops treatments for patients suffering from thromboembolic disease

$100MGrowth

Role not disclosed

Feb 18

Provides non-CPAP alternative for Obstructive Sleep Apnea treatment

$38MStrategic

Role not disclosed

Jan 8

Develops medicines targeting historically undruggable protein targets in cancer

$305MSeries F

Role not disclosed